BioSpace News Archive

The Department of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine and FabOverFifty.com, a lifestyle website, will inaugurate a One-Day Medical School (ODMS) on October 25, 2018, to educate women about the critical health issues they’ll be facing during the transitional years after 45,

Technavio analysts forecast the global rosacea treatment market to grow at a CAGR of over 2% during the forecast period, according to their latest market research report.

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones “Woody” Bryan, Ph.D. has been appointed as Senior Vice President of Business Development

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018.

SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has partnered with Charles River Laboratories, which provides products and services that accelerate research and drug development efforts, to expand its small molecule screening collection and maximize its clients’ opportunities to discover hit compounds for their drug discovery projects.

AirXpanders, Inc., (ASX: AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm Tissue Expander System, today announced it successfully closed in August 2018 its underwritten, pro rata, non-renounceable rights offering to raise approximately A$15.7 million

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA® (venetoclax tablets) in combination with rituximab to include information about patients with previously-treated chronic lymphocytic leukemia (CLL) who achieved minimal residual disease (MRD)-negativity in the Phase 3 MURANO trial.

Panel of bioinformatics experts will discuss how data science can play a significant role in biomedical research

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the pivotal Phase III JAVELIN Renal 101 study evaluating BAVENCIO® (avelumab)* in combination with INLYTA® (axitinib)*, compared with SUTENT® (sunitinib) as initial therapy for patients with advanced renal cell carcinoma (RCC).

Weight Watchers International, Inc. (NYSE: WTW) will be added to the S&P MidCap 400 Index effective prior to the open of trading on September 18, 2018. The company will be classified under S&P’s Global Industry Classification Standard (GICS) Specialized Consumer Services Sub-Industry index.